关注
James McAuliffe
James McAuliffe
DPhil in Clinical Medicine, University of Oxford
在 ndm.ox.ac.uk 的电子邮件经过验证
标题
引用次数
引用次数
年份
Hypoxia and HIF pathway in cancer and the placenta
PS Macklin, J McAuliffe, CW Pugh, A Yamamoto
Placenta 56, 8-13, 2017
1222017
Systemic silencing of Phd2 causes reversible immune regulatory dysfunction
A Yamamoto, J Hester, PS Macklin, K Kawai, M Uchiyama, D Biggs, ...
The Journal of Clinical Investigation 129 (9), 3640-3656, 2019
312019
Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy
J McAuliffe, HF Chan, L Noblecourt, RA Ramirez-Valdez, ...
Journal for immunotherapy of cancer 9 (9), 2021
162021
835 Heterologous prime boost viral vector vaccination provides protection against intracranial syngeneic murine glioblastoma
EE Steffke, T Hana, L Latifi, VP Almeida, J McAuliffe, A Wicki, ...
Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023
2023
Heterologous prime-boost viral vector cancer vaccines have protective effects against a syngeneic mouse model of glioblastoma
EE Steffke, L Noblecourt, VP Almeida, A Wicki, J McAuliffe, G Kohanbash, ...
The Journal of Immunology 210 (1_Supplement), 145.12-145.12, 2023
2023
Heterologous prime-boost viral vector vaccines for the treatment of a P1A-expressing BGL-1 glioblastoma model
EE Steffke, J McAuliffe, VP Almeida, A Wicki, L Noblecourt, G Kohanbash, ...
Cancer Research 83 (7_Supplement), 682-682, 2023
2023
Chemotherapy synergizes with cancer vaccines and expands stem-like TCF1+ CD8+ T cells
L Noblecourt, A Wicki, V Pereira-Almeida, J McAuliffe, E Steffke, S Panetti, ...
bioRxiv, 2023.12. 18.572068, 2023
2023
Developing viral vectored vaccines for MAGE-expressing tumours
J McAuliffe
University of Oxford, 2020
2020
系统目前无法执行此操作,请稍后再试。
文章 1–8